NCT06503679

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Midazolam, Repaglinide, Digoxin, and Rosuvastatin in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4100511 (DC-853) Dose 1	Administered orally
DRUG	LY4100511 (DC-853) Dose 2	Administered orally
DRUG	LY4100511 (DC-853) Dose 3	Administered orally
DRUG	Midazolam	Administered orally
DRUG	Repaglinide	Administered orally
DRUG	Digoxin	Administered orally
DRUG	Rosuvastatin	Administered orally

Timeline

• Start date: 2024-07-16
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2024-07-16
• Last updated: 2025-01-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study